Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NECTINIUM-2 trial: what clinicians have said so far
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- NCT07020117 ↗
- Recruiting
- Aktis Oncology, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NECTINIUM-2 ([225Ac]Ac-AKY-1189 in previously treated locally advanced or metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NECTINIUM-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Urothelial Carcinoma Bladder; Triple Negative Breast Cancer (TNBC); Hormone Receptor Positive Breast Adenocarcinoma; Non Small Cell Lung Cancer; Cervical Adenocarcinoma; Colorectal Adenocarcinoma; Head and Neck Cancer
- Interventions
- [225Ac]Ac-AKY-1189 (therapeutic); [64Cu]Cu-AKY-1189 (imaging)
- Arms
- [225Ac]Ac-AKY-1189 · Experimental
- Enrollment
- 150 (estimated)
- Primary outcomes
- Part 1: Number of Patients with Dose-Limiting Toxicities
- Part 1: Occurence of Adverse Events by Severity
- Part 2: Objective Response Rate (ORR)
- Sponsor
- Aktis Oncology, Inc.
- Start
- Aug 22, 2025
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07020117 · updated Sep 17, 2026